Silvia Giunco

Dr. Silvia Giunco

Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Cancer Letters
Verified
Journal Article
Open access
MPMaria Raffaella Petrara
Maria Raffaella Petrara
Silvia GiuncoSilvia Giunco
Silvia Giunco
DSDiego Serraino
Diego Serraino
Riccardo DolcettiRiccardo Dolcetti
Riccardo Dolcetti
Anita De RossiAnita De Rossi
Anita De Rossi
Post-transplant lymphoproliferative disorders (PTLDs) represent the most severe complication of both solid organ and hematopoietic stem cell transplantation. The Epstein-Barr Virus (EBV) is the main driver of PTLD, particularly those occurring early after transplantation. EBV-driven malignancies are associated with selective expression of latent viral proteins, but uncontrolled lytic replication may favor early phases of cell transformation. Besides immunodepression, persistent immune activation and chronic inflammation play an important role in both virus reactivation and expansion of EBV-infected B cells. EBV-induced immortalization requires the expression of telomerase. TERT, the rate-limiting component of the telomerase complex, is central in the switch from the lytic to the latent viral program, and TERT inhibition induces the EBV lytic cycle and cell death. Immunotherapy and combination of EBV lytic cycle inducers with antiviral drugs are promising strategies to improve the treatment of PTLD patients. This review is aimed at providing an update on the intriguing association between EBV and PTLD, mainly focusing on cases arising after kidney and liver transplantation, which account for the vast majority of transplants.

15 March 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Stefano IndraccoloStefano Indraccolo
Stefano Indraccolo
GLGiuseppe Lombardi
Giuseppe Lombardi
Matteo FassanMatteo Fassan
Matteo Fassan
LPLorenza Pasqualini
Lorenza Pasqualini
Silvia GiuncoSilvia Giunco
Silvia Giunco
VZVittorina Zagonel
Vittorina Zagonel
Purpose: In-depth characterization of recurrent glioblastoma (rGBM) might contribute to a better understanding of the mechanisms behind tumor progression and enable rGBM treatment with targeted drugs. Experimental Design: In this study, GBM samples were collected at diagnosis and recurrence from adult patients treated with Stupp protocol. Expression of mismatch repair (MMR) proteins was evaluated by IHC, followed by whole exome sequencing (WES) of tumor samples showing loss of MSH6 reactivity. Established genetic, epigenetic, and immunologic markers were assessed by standard methods and correlated with loss of MMR proteins and patient survival. Results: Expression of MMR proteins was partially or completely lost in 25.9% rGBM samples. Specifically, 12 samples showed partial or total MSH6 expression reduction. Conversely, 96.4% of GBM samples at diagnosis expressed MMR markers. WES disclosed lack of variants in MMR genes in primary samples, whereas two MSH6-negative rGBM samples shared a c.3438+1G>A* splicing MSH6 variant with a potential loss of function effect. MSH6-negative rGBM specimens had high tumor mutational burden (TMB), but no microsatellite instability. In contrast, GBM samples with partial loss of MMR proteins disclosed low TMB. MMR-deficient rGBM showed significant telomere shortening and MGMT methylation and are characterized by highly heterogeneous MHC class I expression. Conclusions: Multilevel profiling of MMR-deficient rGBM uncovered hypermutated genotype uncoupled from enriched expression of immune-related markers. Assessment of MHC class I expression and TMB should be included in protocols aiming to identify rGBM patients potentially eligible for treatment with drugs targeting immune-checkpoint inhibitors.

1 October 2006 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Daniela BassoDaniela Basso
Daniela Basso
EGEliana Greco
Eliana Greco
PFPaola Fogar
Paola Fogar
PPPiero Pucci
Piero Pucci
AFAngela Flagiello
Angela Flagiello
MPMario Plebani
Mario Plebani

1 January 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero
ANA. Lo Nigro
A. Lo Nigro
DBD. Bernardi
D. Bernardi
Silvia GiuncoSilvia Giunco
Silvia Giunco
GBG. Baldo
G. Baldo
LPL. Punzi
L. Punzi

20 September 2011 in Haematologica
Verified
Journal Article
Open access
PDF file
EREnrica Rampazzo
Enrica Rampazzo
LBL. Bonaldi
L. Bonaldi
LTLIVIO TRENTIN
LIVIO TRENTIN
CVC. Visco
C. Visco
SKS. Keppel
S. Keppel
Anita De RossiAnita De Rossi
Anita De Rossi
Background B-cell chronic lymphocytic leukemia is a clinically heterogeneous disease; some patients rapidly progress and die within a few years of diagnosis, whereas others have a long life expectancy with minimal or no treatment. Telomere length and telomerase levels have been proposed as prognostic factors; however, very few cases have been characterized for both parameters and no study has analyzed the prognostic value of the telomere/telomerase profile. Design and Methods One hundred and seventy-three cases of chronic lymphocytic leukemia were characterized for telomere lengths and telomerase levels by real-time polymerase chain reaction. Data were correlated with established prognostic markers, IGVH mutational status and chromosomal aberrations, and clinical outcome. Results Telomere lengths were inversely correlated with telomerase levels (rs= −0.213; P=0.012), and most of the cases of chronic lymphocytic leukemia with high levels (above median) of telomerase had short (below median) telomeres (P=0.0001). Telomerase levels were higher and telomeres were shorter in unmutated IGVH cases than in mutated IGVH ones (P<0.0001). Chronic lymphocytic leukemias with 11q, 17p deletion or 12 trisomy had significantly higher levels of telomerase and shorter telomeres than those with no chromosomal aberration or the sole 13q deletion (P<0.001). Telomere length/telomerase level profiles identified subgroups of patients with different clinical outcomes (P<0.0001), even within the subsets of chronic lymphocytic leukemia defined by IGVH mutational status or chromosomal aberrations. Short telomere/high telomerase profile was independently associated with more rapid disease progression. Conclusions Comprehensive analyses of telomeres, telomerase, chromosomal aberrations, and IGVH mutational status delineate groups of chronic lymphocytic leukemias with distinct biological characteristics and clinical outcomes. The telomere/telomerase profile may be particularly useful in refining the prognosis of chronic lymphocytic leukemia patients with mutated IGVH and no high-risk chromosomal aberrations.

8 August 2016 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
PBPaolo Boscolo-Rizzo
Paolo Boscolo-Rizzo
MMMaria Cristina Da Mosto
Maria Cristina Da Mosto
EREnrica Rampazzo
Enrica Rampazzo
Silvia GiuncoSilvia Giunco
Silvia Giunco
AMAnnarosa Del Mistro
Annarosa Del Mistro
Anita De RossiAnita De Rossi
Anita De Rossi
Strongly associated with tobacco use, heavy alcohol consumption, and with high-risk human papillomavirus (HPV) infection, head and neck squamous cell carcinoma (HNSCC) is a frequently lethal, heterogeneous disease whose pathogenesis is a multistep and multifactorial process involving genetic and epigenetic events. The majority of HNSCC patients present with locoregional advanced stage disease and are treated with combined modality strategies that can markedly impair quality of life and elicit unpredictable results. A large fraction of those who undergo locoregional treatment and achieve a complete response later develop locoregional recurrences or second field tumors. Biomarkers that are thus able to stratify risk and enable clinicians to tailor treatment plans and to personalize post-therapeutic surveillance strategies are highly desirable. To date, only HPV status is considered a reliable independent predictor of treatment response and survival in patients with HNSCC arising from the oropharyngeal site. Recent studies suggest that telomere attrition, which may be an early event in human carcinogenesis, and telomerase activation, which is detected in up to 90 % of malignancies, could be potential markers of cancer risk and disease outcome. This review examines the current state of knowledge on and discusses the implications linked to telomere dysfunction and telomerase activation in the development and clinical outcome of HNSCC.